Gritstone’s Cancer Drug Shows Strong Tumor-Specific Responses In Various Settings
Gritstone bio Inc (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy…
After Surprise Overall Survival Data In Metastatic Breast Cancer, Gilead Takes Complete Rights To Trodelvy
Everest Medicines will transfer all development and commercialization rights of Trodelvy (sacituzumab govitecan) to Gilead Sciences Inc (NASDAQ:GILD) in Greater China, South…
Palatin Reports Interim Analysis In Phase 3 Pivotal Study Of PL9643 In Patients With Dry Eye Disease
Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today
Recap Of Monday’s Biotech Catalysts – End Of the Day Summary
Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy…
Inhibrx Announces European Medicines Agency Grants Orphan Drug Designation To INBRX-109 For The Treatment Of Chondrosarcoma
Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced that the European Commission ("EC"), based on a positive opinion
Sun, Water, Weed And B2B?: What Opportunities Can Cannabis Investors Expect From This Conference In Panama
By Franca Quarneti via El Planteo.
Why IDEAYA Biosciences Shares Plunging Today
Earlier today, IDEAYA Biosciences Inc (NASDAQ:IDYA) reported Q2 results, and shares have plunged 30% after the update. Investors are probably reacting…
ContraFect Cuts Workforce After Trial Setback
ContraFect Corporation (NASDAQ:CFRX) said it continues to advance lead programs toward new clinical studies and expects to file with regulatory authorities…
Horizon Therapeutics Inks Option Agreement For Atopic Dermatitis Candidate
Q32 Bio and Horizon Therapeutics plc (NASDAQ:HZNP) entered into a collaboration and option agreement to develop ADX-914 for autoimmune diseases. ADX-914 is…
Is Moderna Preparing To Soar 20% And Tackle This Big Level? What To Watch On The Weekly Chart
Moderna, Inc (NASDAQ: MRNA) spiked up almost 5% off Friday’s closing price at one point on Monday, before hitting a resistance level at the $179 level and running into a group of sellers.